5‐Alpha reductase inhibitors in androgenetic alopecia: Shifting paradigms, current concepts, comparative efficacy, and safety. Issue 3 (24th April 2020)

• Record Type: Journal Article
• Authors: Dhurat, Rachita; Sharma, Aseem; Rudnicka, Lidia; Kroumpouzos, George; Kassir, Martin; Galadari, Hassan; Wollina, Uwe; Lotti, Torello; Golubovic, Masa; Binic, Iva; Grabbe, Stephan; Goldust, Mohamad
• Is Part Of: Dermatologic therapy. Volume 33:Issue 3(2020)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2020-04-24
• Subjects: 5‐alpha reductase inhibitors -- androgenetic alopecia -- dutasteride -- finasteride; Skin -- Diseases -- Periodicals; Dermatology -- Periodicals; 616.5
• DOI: 10.1111/dth.13379
• Languages: English
• ISSNs: 1396-0296

Abstract

Abstract: Androgenetic alopecia (AGA) is a multifactorial disease that carries a significant psychological burden with it. Dihydrotestosterone, the main pathogenic androgen in AGA, is produced by conversion of testosterone, which is catalyzed by the 5‐alpha reductase (5‐AR) isoenzyme family. Finasteride and dutasteride are inhibitors of these enzymes. Finasteride, which is a single receptor 5‐alpha reductase inhibitor (5‐ARI), acts by blocking dihydrotestosterone (DHT). Dutasteride, a dual receptor DHT blocker, has a higher potency than its predecessor, finasteride. This review corroborates the evidence of superiority of dutasteride over finasteride, and its comparable safety profile concerning fertility, teratogenicity, neurotoxicity, and hepatotoxicity.